Advertisement

But because Regeneron’s drug is still under clinical trial, they can grant access to the medication via “compassionate use.” In other words, according to the New York Times, the drug is available by request “if all other options have failed and a patient might die without trying the drug.”

This doesn’t necessarily mean that Trump is on death’s door. It could simply underscores that, as president, he can operate as an exception to the rule and access whatever treatment he wants. But his transfer to Walter Reed certainly presents more questions than answers.

Advertisement

Either way, it looks like hydroxychloroquine was left on read.


Advertisement
Advertisement
Advertisement
Advertisement
Advertisement